欧盟HMA药品数据库(European Union HMA Authorisation of Medicines DataBase)
MR编号
NL/H/4081/005
药品名称
Lenalidomide Synthon 15 mg
活性成分
lenalidomide 15.0 mg
剂型
Capsule, hard
上市许可持有人
Synthon B.V.
参考成员国 - 产品名称
Netherlands (NL)
Lenalidomide Fresenius Kabi 15 mg
互认成员国 - 产品名称
Malta (MT)
Italy (IT)
Poland (PL)
Lenalidomide Fresenius Kabi
Portugal (PT)
Austria (AT)
Slovenia (SI)
Lenalidomid Fresenius Kabi 15 mg trde kapsule
Norway (NO)
United Kingdom (Northern Ireland) (XI)
许可日期
2018/08/08
最近更新日期
2024/12/13
药物ATC编码
L04AX04 lenalidomide
申请类型
TypeLevel1:
Known Active Substance
TypeLevel2:
Additional Strength/Form
TypeLevel3:
Generic Art 10.1 and 10.2 Dir 2001/83/EC
TypeLevel4:
Chemical Substance
TypeLevel5:
Prescription Only
附件文件下载
PubAR
|
190214 NL_H_4081_001_007_DC Lenalidomide Synthon PAR
Date of last change:2024/09/06
PubAR Summary
|
190214 NL_H_4081_001_007_DC Lenalidomide Synthon summary EN
Date of last change:2024/09/06
Final SPC
|
smpc_lenalidomide_sep_2021_V006_common_clean
Date of last change:2024/09/06
市场状态
Positive
©2006-2025
Drugfuture
->
European Union HMA Authorisation of Medicines DataBase